Five things for pharma marketers to know: Thursday, May 19, 2016

1. Novartis plans to conduct new clinical trials for heart-failure drug Entresto as it seeks to combat low sales of the drug. The trials, in part, will aim to gather data to address physicians' concerns about switching patients to Entresto. (Reuters)

2. The U.S. spends more on mental health than any other condition, according to a new study published in Health Affairs. Caring for patients with mental health disorders cost the U.S. $201 billion in 2013. (Politico)

3. The FDA approved Roche's immunotherapy Tecentriq as a treatment for advanced bladder cancer. The drug will cost about $12,500 per month. (WSJ)

4. A new report from BIO found that 2015 was the best year on record for U.S. venture capital funding. Companies raised about $7 billion, led by funding for developers of immuno-oncology and neurodegenerative disease treatments.

5. In other Novartis news, the drugmaker said it halted a clinical trial for an experimental breast-cancer drug because the therapy met its goal of significantly extending the time patients lived, without the disease progressing. If approved, the drug will compete will Pfizer's Ibrance. (Reuters)